Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Short position
Neuren Pharmaceuticals (ASX:NEU) has 2.95% of its shares on issue reported as short positions as of 5 Oct 2026, or about 3,735,393 shares. Over the past 30 days that figure has fallen 0.08 percentage points, and over 90 days it has fallen 1.96 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Neuren Pharmaceuticals (NEU) short interest history
NEU Short Interest History
- 30-day change
- -0.08pp
- 90-day change
- -1.96pp
- 1-year change
- -2.25pp
- All-time high
- 6.51% (June 2026)
- All-time low
- 0.00% (May 2019)
Is NEU heavily shorted?
Not especially: 2.95% short interest is modest by ASX standards, ranking #116 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has NEU's short interest changed recently?
Over the past 30 days Neuren Pharmaceuticals's short interest has been broadly stable, and over 90 days it has fallen 1.96 percentage points. The current level is 2.95% of shares on issue.
What is the highest NEU's short interest has been?
Since 2012, Neuren Pharmaceuticals's short interest peaked at 6.51% in June 2026 and bottomed at 0.00% in May 2019.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2012. See our methodology.